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EPISODIC MEMORY PERFOMANCE AND ASSOCIATED GREY MATTER 
VOLUME IN OLDER ADULTS WITH TYPE 2 DIABETES MELLITUS 
SADHVI SAXENA 
ABSTRACT 
 Type 2 Diabetes Mellitus (DM2) results in peripheral and central nervous system 
complications. Recent studies suggest that DM2 accelerates age-related cognitive decline 
and is specifically linked to Alzheimer Disease (AD). A commonly reported impairment 
reported in DM2 is in learning and memory, and macroscopic brain changes that could 
mediate memory impairments can be detected by quantifying grey matter volume with 
Magnetic Resonance Imaging (MRI). This thesis project predicts that older adults in 
DM2 have impaired learning and memory compared with older adults without DM2. 
Additionally, the DM2 group would have decreases in grey matter volume of the 
hippocampus and associated brain regions, which would mediate memory function. The 
study found that the DM2 group performed significantly worse on two validated 
neuropsychological measures of learning, recall and recognition. The difference was 
highly significant in the learning and memory of face-name pairs, suggesting that 
assessing higher-level memory functions could be a sensitive marker for subtle memory 
impairments. However, the two groups did not differ in grey matter volume of the 
hippocampus, the medial temporal lobe, or the hippocampal network. Additionally, grey 
matter volume was not associated with learning and memory measures. The findings 
suggest that memory changes in DM2 may not be mediated by brain atrophy, rather could  
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be mediated by microscopic brain changes earlier in AD progression such as beta 
amyloid accumulation, hyperphosphorylated tau protein, or reduced synaptic plasticity. 
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INTRODUCTION 
Type II Diabetes Mellitus  
 
Diabetes Mellitus (DM) affects approximately 29 million people in the United 
States. 8 million of these cases are undiagnosed and therefore untreated.1 Type II 
Diabetes Mellitus (DM2) is referred to as latent-onset diabetes and accounts for 90 to 
95% of all diagnosed cases of DM.2  In cases of DM2, beta cells of the pancreas are 
unable to secrete enough insulin in response to elevated blood glucose levels. In addition, 
insulin resistance occurs in DM2.3 Insulin resistance refers to an inadequate response to 
insulin by its target in muscle, liver and adipose tissues, and therefore these cells do not 
respond to the to the physiological effects of insulin. 4,5 DM2 is diagnosed when there are 
fasting blood glucose levels higher than 126 mg/dL, glycosylated hemoglobin A1c 
(HbA1c) levels of 6.5% or higher, or glucose levels higher than 200 mg/dL 2 hours after 
an oral glucose tolerance test.3 
DM2 is a major cause of disability and death. It is well known that individuals 
with DM2 develop neurological complications, such as peripheral neuropathy and 
resultant sensory loss, weakness, gait disturbances, balance problems and pain in the feet 
or hands. Alterations in autonomic nervous system activity also occur, including slowed 
digestion or erectile dysfunction.2   Such complications of the peripheral and autonomic 
nervous system can be detected early, characterized, and also followed longitudinally 
using neurophysiological techniques.2 Central nervous system (CNS) damage is also 
common in DM2, but the neurobiological substrates and clinical profile of these changes 
are less clear.6 
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Relationship Between DM2 and Alzheimer Disease (AD) 
Several studies have examined the aforementioned CNS changes and found that 
DM2 accelerates brain aging.7–12 Likely as a result of DM-related damage to the CNS, 
older adults with DM2 also show both cognitive and functional impairments compared 
with controls.13 DM2-related cognitive impairment, in particular, has been consistently 
reported in cross-sectional, case-control and longitudinal studies.6,9,12,14–22 Furthermore, 
small clinical trials demonstrate that control of DM2 is associated with improvements in 
cognitive functioning21,23–25, and improvements in glycemic control can partially reverse 
cognitive dysfunction.26 However, the benefits of glucose management in DM2 remain 
under debate. Results from a recent, large-scale clinical trial demonstrated that those with 
DM2 showed no cognitive benefit from glucose management.27,28 Thus, the causal 
relationship between DM2 and cognitive functioning remains unresolved. 
 The most commonly reported changes in DM2 are in learning and memory, 
mental flexibility and mental speed.7,8,15 These changes are shown as early as the pre-
diabetes phase where individuals have elevated glucose levels below the threshold for 
DM2 diagnosis.29 The aforementioned changes in memory have been of great interest in 
the literature because impairments in memory are a hallmark of Alzheimer Disease (AD). 
AD is a neurodegenerative disorder that makes up about 50% of all dementia cases.30 It 
affects about 5 million Americans,3 but these numbers are expected to triple by 2050.31  
AD is a progressive neurodegenerative disease, and its neuropathological changes 
occur prior to the cognitive changes that are used to guide AD diagnosis.2 However, by 
this point, there is irreversible brain damage from beta-amyloid deposition, 
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hyperphosphorylated tau protein accumulation, reduced synaptic plasticity and resulting 
atrophy from neuronal loss (Sperling 2011). Mild cognitive impairment (MCI) is the 
transitional phase before AD where there are neuropsychological changes, but not enough 
to be diagnosed as dementia.46,47 Only those with amnestic MCI (aMCI) go on to develop 
dementia.33 As a result, much effort has been made to detect risk factors of AD that put 
individuals in stages of preclinical dementia, prior to the development of cognitive 
symptoms. These could serve as targets for early intervention and prevention of cognitive 
decline. The changes that occur and their time course are demonstrated in Figure 1. 
 
Figure 1: Time course of brain changes in preclinical, MCI, and AD. AD pathology 
begins with beta amyloid deposition, which alters synaptic plasticity. There is then 
neuronal injury and loss from hyperphosphorylation of the tau protein, leading to brain 
atrophy. These brain changes occur prior to MCI, where only a subset of these 
individuals proceeds to develop AD. At AD diagnosis, permanent brain damage and 
cognitive abnormalities have already occurred.  
 
Preclinical MCI Dementia
Abnormal
Clinical manifestation
Brain atrophy
Tau-mediated neuronal injury
Altered plasticity
β-Amyloid deposition
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Many studies have found that DM2 is associated with an increased risk of 
developing AD.2,34–36. It is also known that patients with AD are at an increased risk of 
developing reduced insulin resistance,37 with up to 80% of all cases of AD having a 
diagnosis of DM2 or elevated fasting glucose levels.38 The prevalence of both DM2 and 
AD increase with age, and as their incidence increases rapidly, the complications and 
underlying mechanisms that link the two diseases must be addressed. 
Underlying Mechanisms That Link Type 2 Diabetes and Alzheimer Disease 
   
AD is well characterized by pathological features including beta amyloid 
deposition, neurofibrillary tangles of hyperphosphorylated tau protein, as well as cerebral 
inflammation.39 The mechanisms that underlie brain changes in DM2, on the other hand, 
are unclear. DM2 is caused by a combination of physiological, genetic and lifestyle 
factors,30 making it a complex metabolic disorder with many variations and 
comorbidities.40,41 Studies have suggested that increased glucose levels lead to neuronal 
dysfunction and resulting neuronal loss, which may result in AD-like brain changes. 
Insulin resistance from DM2 also occurs the brain, as the insulin receptor signal 
transduction pathway is perturbed. As a result, there is reduced glucose metabolism in the 
brain42–44 and neuronal dysfunction. Rodent models suggest that these insulin receptors 
are mainly localized in areas of the brain that mediate learning and memory performance, 
including the hippocampus, prefrontal cortex and the cingulate gyrus.38,45,46 Therefore, 
abnormal glucose metabolism as a result of DM2 may have a negative effect on memory 
performance, increasing the risk of developing AD. 
Brain changes as a result of insulin resistance and compensatory hyperinsulinemia 
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resemble AD pathology. DM2 interferes with amyloid metabolism by facilitating 
amyloid secretion and interfering with amyloid breakdown,38,41,47,48  and insulin 
dysfunction leads to tau hyperphosphorylation.48,49 Lastly, elevated plasma insulin levels 
are associated with elevated inflammatory markers such as C-reactive protein and 
interleukin-6,50 which would make individuals receiving insulin for DM2 treatment more 
prone to cerebral inflammation.  
Recent interventional studies have shown that diabetes medications, such as 
insulin, can improve memory performance in patients with AD, which has also been 
shown in rodent studies as well.51 A combination of insulin and other diabetes medication 
has also lowered neuritic plaque density in patients with AD.52 These studies provide 
further evidence that brain insulin resistance contributes to cognitive impairment in mild 
cognitive impairment (MCI), dementia and AD.53,54  
Nonetheless, many questions need to be answered, as pathological studies have 
failed to confirm the link between DM2 and AD on a microscopic level.55,56 While 
underlying mechanisms are unresolved, there is a critical need for the parallel 
development of surrogate markers for macroscopic CNS changes that can be localized 
and prevented, or at least treated early in the disease progression. 
Shared Memory Impairments DM2 and AD  
 
Given that DM2 is associated with an increased risk of cognitive decline and AD, 
and that insulin receptors in the brain are localized in the hippocampus, much focus has 
been on examining memory changes in individuals with DM2. Episodic memory, the 
ability to remember concrete and personal experiences,57 is a common cognitive 
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impairment in amnestic MCI and AD.57 It is also shown in cases of DM2.2 Verbal 
memory is a type of explicit declarative memory, and neuropsychological measures of 
verbal learning tests reflect the ability to retain new information.57 Verbal memory 
assessments are commonly used tools of memory impairments in dementia and 
preclinical AD.10,12,15,20,58,59  
Learning and memory impairments are a signature of early AD. Given that the 
clinical symptoms of these changes only occur after pathological changes in AD have 
progressed, they may not be sufficient to detect mild changes in cognition that occur 
before the onset of irreversible changes. More recently, researchers have been focusing 
on asymptomatic individuals who are at preclinical AD phases, so that the risk for 
developing symptoms of AD can be detected and treated prior to disease onset. One such 
cognitive process is the daily task of learning the name of someone that one meets, and 
remembering this face-name association. This daily task is especially challenging 
because the association is inherently unrelated.60 Additionally, it becomes even more 
challenging as one’s age progresses.61 Recent Positron Emission Topography (PET) and 
postmortem pathological studies have shown that  “asymptomatic” individuals, free of 
cognitive complaints but nonetheless perform worse at paired-associate memory tasks, 
have higher levels of beta amyloid in the brain.61 Researchers then developed 
neuropsychological measures that are sensitive to these subtle memory impairments of 
what investigators have called preclinical AD,61,62 and that lead to the buildup of beta-
amyloid. If these paired-associative memory changes are detected in DM2, then 
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interventions could be targeted before irreversible brain damage from substantial 
neuronal loss and neuropathological changes occur that lead to symptoms of AD. 
Using Magnetic Resonance Imaging to Explore Macroscopic Changes in Type 2 
Diabetes Mellitus 
 
Since several studies have shown that DM2 is associated with impairments in 
memory that resemble preclinical AD, aMCI or AD, it is important to detect the neural 
correlates of these changes. One way to localize the macroscopic correlates of these 
changes is through Magnetic Resonance Imaging (MRI). MRI is a sensitive tool that is 
used to detect biomarkers of neurological diseases. In particular, structural MRIs can be 
used to quantify grey matter volume differences63 and thus identify regions that may be 
shrinking due to neuronal loss.  
Structural MRI studies have shown that AD progression starts in the limbic 
regions of the brain, and spread through the temporal, parietal and frontal lobes as the 
disease progresses.64 Specifically, early stages of AD demonstrate atrophy in the 
hippocampus and entorhinal cortex in the medial temporal lobe (MTL).65 aMCI 
pathology also starts in the entorhinal cortex and hippocampus66 and can be detected as 
early sites of abnormalities prior to the development of AD.  
Similarly, there is reduced hippocampal volume in DM2,20,58,67–72 as well as lower 
volumes of other MTL structures such as the entorhinal cortex.68,73 This association has 
also been reported in adolescents with DM244 and elderly people with prediabetes.74 The 
similarities in MTL structural changes are supported by evidence that DM2 is associated 
with an accelerated progression from MCI to dementia,75 and that individuals with DM2 
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and MCI have greater reduction in hippocampal volume than individuals with only 
MCI.33 
The process of memory formation and retrieval, however, is not limited to the 
hippocampus and entorhinal cortex. Recently, it has been shown that many cognitive 
processes are driven by the dynamic communication between large-scale neural 
networks.76 Thus, memory depends on more than just the hippocampus and the medial 
temporal lobe.77 This network has been identified by functional MRI (fMRI) and PET 
studies and is known as the default mode network (DMN).78 The regions that make up the 
DMN are functionally connected with the hippocampus and are consistently reported in 
episodic memory and paired-associative memory formation. Disruptions of the DMN and 
resultant disconnectivity are being explored as neural substrates for cognitive disorders, 
as they deactivated during cognitive tasks such as hippocampal-dependent memory tasks. 
The episodic memory network that is impaired in AD includes the medial temporal lobe 
structures (hippocampus, entorhinal cortex, parahippocampus, amygdala), as well as 
medial and lateral parietal areas of the default mode network (precuneus/posterior 
cingulate, angular gyrus) 77,7879 Atrophy in this network of regions can be detected 
through structural imaging in very mild stages of AD or even preclinical AD.77,80,81 
Furthermore, DMN alterations also overlap with amyloid deposition in AD.82,83   
Although there is no concrete evidence that amyloid plaques are accumulated in 
DMN regions in cases of DM2, there is evidence that poor glycemic control and high 
insulin resistance are also associated with reduced gray matter volume in the episodic 
memory network regions including the amygdala, prefrontal cortex and precuneus.2,34–36 
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Studies have also found gray matter atrophy in bilateral hippocampal regions and also 
temporal, frontal and cingulate cortices.84 However, there are still substantial gaps to fill 
as to whether hippocampal and memory changes in DM2 are even related, as several 
studies have failed to show this association.20,72  
Specific Aims and Objectives  
 
Given the limited evidence linking structural brain changes to cognitive 
performance, there is a need for additional studies that relate grey matter volume 
reductions to cognitive dysfunction. More studies are needed to assess if structural brain 
changes play a mediating role in the association between DM2 and memory performance. 
The hypothesized mediating effect is shown in Figure 2.  
 
 
 
 
 
 
 
 
 
Figure 2: Accelerated brain aging due to DM2. As age increases, grey matter volume 
decreases and cognitive dysfunction increases. These changes occur due to normal aging, 
but DM2 may lead to accelerated brain aging, caused by gray matter volume reductions 
and resulting cognitive impairments.  
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The presented analysis focuses on two types of memory with well-known 
involvement in early or preclinical stages of AD: verbal learning and memory and paired-
associative memory. These two measures will be used to investigate the etiology of brain 
damage in DM2. This analysis aimed to localize differences in cortical volume in regions 
of the DMN associated with episodic and paired-associative memory in individuals with 
DM2 compared with healthy controls.  
The study investigates whether there are changes in episodic memory performance in 
older adults with DM2, and if these changes are mediated by reductions in grey matter 
volume of the hippocampus and associated brain regions. The specific aims of the study 
include the following:  
1. To determine if DM2 is a predictor of impairments in learning and memory 
compared with controls.  
2. To determine if DM2 is a predictor of reductions in grey matter volume in the 
hippocampus and associated regions.  
3. To determine if memory performance is associated with grey matter volume in 
brain regions associated functionally with learning and memory. 
Study Rationale 
Ultimately, this analysis aims to contribute to the idea that individuals with DM2 
are at high risk of cognitive decline and AD-like pathologies. Additionally, specific 
structural changes can be targets for early detection and prevention of cognitive decline 
that results from DM2. Currently there are no ways of reversing cognitive decline. If 
DM2 is a risk factor for AD, and if the cognitive and neural substrates are well 
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characterized, then these can be targets of early prevention and intervention to ultimately 
decrease the public health burden of these diseases on our aging population. 
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METHODS  
Subject Population 
 
        This secondary analysis of a cross-sectional study included individuals DM2 
between the ages of 50 and 80 years old, and healthy controls between 50 and 80 years 
old. DM2 subjects were recruited in part through physician-approved letters sent to 
patients of the Joslin Diabetes Center. In addition, DM2 and control subjects were 
recruited through flyers posted around the Beth Israel Deaconess Medical Center. All 
potential participants were prescreened on the phone for eligibility, and all study sessions 
took place at the Beth Israel Deaconess Medical Center. The study protocol was approved 
by the Institutional Review Board at the Beth Israel Deaconess Medical Center 
(BIDMC).  
Inclusion for DM2 subjects included a confirmed diagnosis of DM2, treatment of 
DM2 through diet and/or medication, and HbA1c levels of 10% or less, indicating 
diabetes that is well controlled. For the control subjects, inclusion criteria included 
normal fasting glucose (< 100 mg/dl) and HbA1c levels (< 6.4%), no evidence of 
dementia, and a minimum completion of 8th grade education. Subjects in both groups 
were excluded if they had any unstable health condition, as well as standard exclusion 
criteria for MRI (e.g., implanted devices or ferrous metal in the body). Specific exclusion 
criteria included: any significant macrovascular disease including cardiovascular disease, 
peripheral vascular disease or stroke; significant microvascular disease including vision 
impairing retinopathy, severe neuropathy or renal insufficiency; history of serious 
neurological disorders affecting cognitive function; past or current history of major 
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depression or any other major psychiatric condition; history of neurodevelopmental 
disorders or intellectual disability; any metal in the brain, skull, or elsewhere in the body 
that are not MRI compatible; or a BMI > 40 due to MRI scanner weight and width limits. 
Screening Procedures, Baseline Measurements, and Neuropsychological Assessment 
 
All participants provided written and verbal consent at the initial screening visit. 
After obtaining informed consent, a Research Nurse at the Harvard Catalyst Clinical 
Research Center (HCCRC) performed a venous blood draw for baseline measurements of 
fasting blood glucose levels, creatinine levels and HbA1c levels.   
Medical history was then collected in a structured clinical interview including a 
review of current medications, history of diabetes, history of high cholesterol, history of 
hypertension, family history of dementia, and history of other medical conditions that 
may exclude subjects from the study. All participants underwent a brief neurological 
examination by a study physician to confirm that the subject was eligible to continue with 
protocol procedures.  
The screening visit also included a standard neuropsychological battery. Tests and 
inventories for baseline characteristics were drawn from the National Alzheimer’s 
Coordinating Center’s Uniform Data Set (NACC-UDS) and consisted of the Geriatric 
Depression Scale (GDS), Mini Mental Status Examination (MMSE). In addition, the 
Alzheimer’s Disease Cooperative Study Activities of Daily Living scale (ADCS-ADL) 
and Weschler Test of Adult Reading (WTAR) were administered to assess functional 
independence, cognitive impairment and general intelligence, respectively.  
Verbal Learning and Paired-Associative Learning Assessment 
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To further probe learning and memory function, two tests were administered. 
Verbal memory performance was measured by a 10-item version of the Rey Auditory 
Verbal Learning Test (RAVLT). The RAVLT reflects the process of encoding, learning, 
recalling and recognizing verbally presented words57 and is a validated predictor of 
conversion to AD.85,86 Each participant was read a list of 10 semantically unrelated words 
in 5 consecutive trials. After each list is given, the participant was asked to immediately 
recall as many words as possible. After 20 minutes, participants were asked to recall as 
many words as possible from the same list. There are three outcomes from the RAVLT 
task. Immediate recall, indicative of verbal learning, was scored as the average words 
correctly recalled over the 5 trials. Delayed recall was calculated as the proportion of 
correct words recalled after a 20-minute delay. Delayed recognition was calculated as the 
proportion of correct words recalled after a verbal cue.  
Paired-associative memory was assessed by the Face Name Associative Memory 
Exam (FNAME). The FNAME is a validated tool to assess paired-associative memory 
performance of names and occupations at initial retrieval, cued retrieval, and delayed 
retrieval after a 30 minute delay. The FNAME task is a tool for dissociating memory 
impairments related to preclinical AD from those associated with normal aging.87 
Participants were presented 12 faces with names and occupations written below, and 
were given 8 seconds to read aloud and remember the name and occupation that went 
with each face. At the end of the first trial, the participants were shown each face in the 
same order, and they were asked to recall the name and occupation. Each participant was 
given a second learning trial with the faces presented in a different order. The composite 
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score of the two learning trials was calculated as the participant’s learning ability. During 
short delay of 4 to 5 minutes, participants were administered a distractor task. In this task, 
they were shown a company logo and were then asked to name the company to which 
each logo corresponds, as well as the product of the company. After this distractor task, 
participants were again shown the 12 faces and asked to recall the name and occupation 
with each face. The total names and occupations correctly recalled after the distractor 
task comprised of recall scores. After a 30-minute delay, participants were shown 3 faces, 
and had to determine which face they recognized from before. Then, participants were 
asked to recall the name and occupation of the face. The total number of names and 
occupations recalled comprised the recognition score. The composite of each subscale 
will be used as the primary outcome for paired-associative memory. Face-name retrieval 
(combined learning, recall, and recognition) and face-occupation retrieval (combined 
learning, recall, and recognition) scores will be assessed. Lastly, individual subscale 
scores will be assessed to isolate the memory functions assessed in this task: learning, 
recall and recognition. A diagram outlining the administration of the FNAME task is 
presented in Figure 3.  
 
	  16 
 
Figure 3: Face Name Associative Memory Exam (FNAME) Administration 
Sequence. The task begins with learning trials of reading and remembering the name and 
occupation that goes with each face. Then, learning of the names and occupation that 
belong to each face is assessed. After a distractor task, the participants are shown the 
faces again and asked to recall the name and occupation, assessing recall. After a 30-
minute break, participants were shown the faces again and asked to recall the names and 
faces to assess recognition, as they were cued by recognizing the face.  
 
ROI selection 
Regions of interest (ROIs) for MRI analysis were selected a priori from a review 
of literature related to imaging memory networks in dementia. ROIs included the 
hippocampus and surrounding entorhinal cortex, parahippocampus, amygdala, posterior 
cingulate/precuneus, and angular gyrus. These regions have been associated with learning 
and memory performance and collectively comprise the default mode network, a resting-
state network that is disrupted in early stages of dementia.     
MRI acquisition and Image Processing 
Each participant’s MRI was performed on BIDMC’s 3T Signa MR scanner (LX 
15, GE Healthcare, Illinois) using an 8-channel proton head coil. A 3D spoiled gradient 
echo sequence was used with the following parameters: 162 axial-oriented slices for 
whole-brain coverage; 240 mm isotropic field-of-view; 0.937 mm x 0.937 mm x 1 mm 
native resolution; flip angle = 15°; TE/TR ≥ 2.9/6.9 ms; duration ≥ 432 s. Individual 
images were processed using the recon-all pipeline in Freesurfer (Martinos Center for 
Biomedical Imaging, Boston, MA, USA).  
Statistical Analysis 
Descriptive statistics were used to compare all variables between groups, 
including education level, MMSE score, GDS score, ADL score, HbA1c levels, fasting 
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glucose levels, creatinine levels, and BMI. A Student’s t-test for independent means was 
used to assess differences for continuous variables, and a Chi-squared test was used for 
categorical variables. 
Episodic Memory Performance Analysis 
 Between-group differences in verbal learning, delayed recall, and delayed 
recognition on the RAVLT were compared using a Student’s t-tests for independent 
means. Between-group differences in initial name recall, cued name recall, and 30-
minuted delayed cued recall were compared using a Student’s t-test for independent 
means. 
Grey Matter Volume Analysis 
MRI analysis was performed using FreeSurfer Image Analysis Suite, Version 
4.0.2, which was downloaded online at http://surfer.nmr.mgh.harvard.edu.88 FreeSurfer 
processes and normalizes each individual MRI, and performs grey matter volume 
calculations after automatic parcellation and segmentation of the regions of interest based 
on a predefined atlas.89 For each individual, grey matter volume for each ROI was 
calculated as the proportion of gray matter volume (cm3) in the selected ROI over the 
estimated Total Intracranial Volume (eTIV). This method has been suggested to account 
for individual differences in head size that may account for differences in structural 
volume. Differences in proportions of grey matter volume between the groups were 
analyzed using a Student’s t-test for independent means.  
Differences between DM2 and controls in total gray matter volume were also 
analyzed to assess global hippocampal and associated regional atrophy. 
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DM2 and Potential Confounders as Predictors of Outcome Measures 
 
A linear regression model was performed on the outcomes that were significantly 
different between the DM2 and control groups at a p <0.05 levels. To assess if DM2 was 
a still significant predictor after adjusting for potential confounds, a linear model was 
created to control for BMI, MMSE, GDS age, sex, and education. Since HbA1c levels are 
reliable predictors of DM2-related brain changes,73 a separate linear regression model 
looked at the association between HbA1c levels and outcome measures when controlling 
for the same variables as the previous model. The analysis did not create a separate model 
for fasting glucose measures, as HbA1c more sufficiently captures the dose-response 
relationship. 
Association Between Memory Performance and Structural Brain Changes 
A linear regression analysis was performed to determine if there is an association 
between cognitive measures and grey matter volume in the targeted areas. An analysis 
was performed within the two groups. In the DM2 group, this association could be due to 
age rather than diabetes status. Associations between HbA1c levels and age in the two 
groups were also assessed as potential predictors that may confound the relationship. For 
significant associations found, a separate model was created to adjust for HbA1c and/or 
age.  	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RESULTS 
Baseline Characteristics 
 
 Table 1 highlights demographic and baseline information collected from the 27 
individuals with DM2 and 26 controls that were administered the RAVLT. Of these 53 
subjects, 15 individuals with DM2 and 15 controls were administered the FNAME task.  
On the Geriatric Depression Scale (GDS), the DM2 group reported significantly 
higher levels of depression than the control group (p=0.023). On average, the DM2 group 
was older, had fewer years of education, had lower global cognitive status (MMSE), 
reported a lower level of functional independence in daily activities (ADL), and scored 
lower on the measure of general intelligence (W-TAR). These differences were not 
significant, suggesting that the two groups were balanced in overall cognitive, functional 
and independence status. However, it is important to note that true differences may not be 
detected due to the small sample size. As expected, the DM2 group had significantly 
elevated HbA1c and fasting glucose levels (p<0.001 for both measures), consistent with 
diabetes status. 
 
 
 
 
 
 
 
	  20 
Table 1: Demographic and Baseline Characteristics. 
 
  
OHC 
 
 
DM2 
Baseline and Demographic Characteristics 
N⌃ 26 27 
Sex  (% Male) 53.8% 55.6% 
Age (years) 
Mean (S.D.) 
Range 
 
61.7 (9.1) 
50-77 
 
66.0 (7.7) 
60-80 
Education (years) 
Mean (S.D.) 
        Range 
 
15.8 (2.4) 
12-21 
 
15.6 (2.6) 
10-20 
BMI (kg/m^2)* 
Mean (S.D.) 
Range 
 
26.4 (4.8) 
19.4-39.2 
 
29.9 (3.8) 
22.6-35.9 
Neurocognitive Status 
MMSE 
Mean (S.D.) 
        Range 
 
29.5 (0.8) 
27-30 
 
29.0 (0.96) 
27-30 
ADL 
Mean (S.D.) 
Range 
 
76.2 (2.6) 
67-78 
 
76.0 (2.6) 
69-78 
GDS* 
Mean (S.D.) 
Range 
 
0.4 (0.8) 
0-3 
 
1.3 (1.8) 
0-7 
W-TAR 
Mean (S.D.) 
Range 
 
113.7 (10.1) 
92-126 
 
112.3 (10.1) 
78-126 
    Diabetes-status  
Fasting glucose (mg/dL)** 
Mean (S.D.) 
Range 
 
89.1 (7.5) 
76-102 
 
138.4 (37.0) 
90-220 
Creatinine 
Mean (S.D.) 
Range 
 
0.84 (0.2) 
0.58-1.3 
 
0.89 (0.2) 
0.62-1.6 
HbA1c (%)** 
Mean (S.D.) 
Range 
 
5.6 (0.3) 
5.1-6.2 
 
7.3 (1.1) 
5.9-9.7 
*p<0.05 
**p<0.001 
⌃ = FNAME administered to 15 OHC and 15 DM2 subjects. 
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-HbA1c collected on 16 HC and 19 DM2, creatinine on 18 HC and 15 DM2, fasting 
glucose on 17 HC and 18 DM2. 
-BMI collected on 21 DM2 and 21 OHC. 
-GDS reported on a scale from 1-13, with higher score indicating greater severity of self-
reported depressive symptoms. 
-ADL has a maximum score of 78, with higher score demonstrating greater functional 
independence in activities of daily living.  
 
Verbal Learning and Memory Results 
 
The DM2 group scored lower on the RAVLT learning, recall and recognition 
subsections compared with controls (Table 2). However, the decrease in performance was 
only significant for immediate recall and delayed recognition measures. Therefore, the 
DM2 group showed impairments in episodic memory retrieval. It is important to note that 
the RAVLT consists of 10 words, and the proportion of correctly recalled words DM2 
group on average was one word less than the control group. 
Table 2: Performance on RAVLT measures (verbal learning, recall and recognition) 
in DM2 group compared with control group. 
 
RAVLT Scores 
(proportion correct) 
OHC (n=26) DM2 (n=27) p-value  
Learning 0.81 (0.1) 0.70 (0.1) 0.0015* 
Recall 0.8 (0.2) 0.7 (0.3) 0.1066 
Recognition  0.98 (0.04) 0.89 (0.11) 0.0015* 
 
Paired-Associative Memory Results  
The DM2 group had significantly lower scores on the face-name measures of the 
FNAME task, but only certain face-occupation measures (Table 3). The DM2 group 
performed significantly worse than the control group on measures of learning face-name 
and face-occupation pairs (p<0.001 and p=0.019, respectively) after the learning trial. 
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Composite FNAME scores, but not FOCC scores, were significantly reduced in the DM2 
group. These results suggest that the mechanism for remembering face-name and face-
occupation associations are different, and that face-name associations are more difficult 
to learn and retrieve in in cases of DM2 compared with controls.  
Table 3: Performance on FNAME measures in DM2 group compared with control 
group. 
 
FNAME Scores 
(number correct) 
OHC (n=15) DM2 (n=15) p-value 
Face-name learning 14.6 (3.8) 8.9 (4.2) 0.0005* 
Face-occupation 
learning 
20.7 (3.0) 17.0 (4.9) 0.019* 
Face-name recall 9.7 (1.9) 5.8 (2.98) 0.0002* 
Face-occupation 
recall 
11.0 (2.0) 9.4 (2.6) 0.0707 
Face-name 
recognition 
9.2 (2.7) 4.8 (2.9) 0.0002* 
Face-occupation 
recognition 
11.0 (1.6) 9.5 (2.1) 0.0300* 
FNAME Task Total 
Score 
76.3 (13.8) 51.7 (17.1) 0.0002* 
Face-name 
cumulative 
(learning, recall 
and recognition) 
33.5 (7.9) 19.9 (10.7) 0.0005* 
Face-occupation 
cumulative 
(learning, recall 
and recognition) 
42.7 (6.6) 38.1 (13.3) 0.24 
Represented by mean (SD) 
*=p<0.05 
 
FNAME and RAVLT Comparison Results 
 Figure 4 outlines that the two groups were similar in general cognition and 
general intelligence, but compared to the control group, performed significantly worse on 
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both measures of learning and memory. Particularly, the DM2 group was significantly 
impaired in the learning, recall, and recognition of face-name pairs compared with 
controls. These results that the FNAME task is a reliable marker of the memory 
impairments that are shown in older adults with DM2. 
 
Figure 4: DM2 performance on RAVLT and face-name measures compared to 
controls. Despite similarities in general cognition and intelligence, the DM2 group 
performed significantly worse on the FNAME (face-name pairs only) measures compared 
to controls. They performed worse on RAVLT measures, but the differences were of 
higher significant in forming and remembering face-name pairs. These results suggest 
that the FNAME task is a more sensitive measure of memory impairments as a result of 
DM2.  
      
Region-of-Interest Gray Matter Volume Results 
 
 Table 4 shows that the DM2 group showed reductions in the left and right 
posterior cingulate cortex, left and right precuneus, left and right angular gyrus, right and 
left angular cingulate cortex, left parahippocampus and right entorhinal cortex. None of 
these reductions were significant, though there was a statistical trend for reductions in 
right posterior cingulate cortex volume (t=1.99, p=0.053). Interestingly, the DM2 group 
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had a higher proportion of grey matter volume in the left entorhinal cortex, but this 
difference was not significant.  
 
 
Table 4: ROI gray matter volume differences (average proportion of gray matter 
volume of ROI/total gray matter volume of each individual) in DM2 group 
compared with control group. 
 
 OHC (n=26) DM2 (n=27) p-value 
Medial Temporal Lobe 
L-hippocampus 0.0026 (0.0003) 0.0026 (0.0004) 0.98 
R-hippocampus 0.0026 (0.0003) 0.0026 (0.0004) 0.55 
L-amygdala 0.0011 (0.0001) 0.0011 (0.0002) 0.68 
R-amygdala 0.0012 (0.0001) 0.0012 (0.0002) 0.63 
L-parahippocampus 0.0013 (0.0003) 0.0012(0.0003) 0.69 
R-parahippocampus 0.0011 (0.0002) 0.0011(0.0003) 0.52 
L-entorhinal 0.00080 (0.0002) 0.00085 (0.0002) 0.35 
R-entorhinal 0.00078 (0.0002) 0.00073 (0.0002) 0.40 
Default Mode Network 
L-posterior cingulate cortex 0.0018 (0.0017) 0.0017 (0.0003) 0.14 
R-posterior cingulate cortex 0.0019 (0.0002) 0.0017 (0.0003) 0.05 
L-precuneus 0.0055 (0.0006) 0.0054 (0.0006) 0.46 
R-precuneus 0.0057 (0.0005) 0.0055 (0.0006) 0.31 
L-angular gyrus 0.0034 (0.0006) 0.0032 (0.0005) 0.22 
R-angular gyrus 0.0040 (0.0007) 0.0037(0.0007) 0.15 
*All values are reported in cm3 
*All GMV calculates are the measure of the ROI as a proportion of estimated Total 
Intracranial Volume to account for differences in head size. 
 
Global Gray Matter Volume Results 
 
Table 5 represents the proportion of total gray matter volume, including both 
cortical and subcortical structures. The total gray matter volume was compared between 
the two groups. Overall, the DM2 group had reduced grey matter volume compared to the 
control group, but this reduction was marginally significant (t=2.04, p=0.05). This 
association was no longer marginally significant after adjusting for age, suggesting that it 
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could be the higher average age of the DM2 group that contributed to the reduction in 
total gray matter volume. 
Table 5: Global gray matter volume differences (average proportion of gray matter 
volume of cortical and subcortical regions/total gray matter volume of each 
individual) in DM2 group compared with controls. 
 
 OHC DM2 t-value p-value 
Total gray 
matter volume 
.40 (0.02) 0.38 (0.05) 2.03 0.05 
*All values are reported in cm3 
*GMV measured as total cortical and subcortical grey matter volume as a proportion of 
estimated Total Intracranial Volume to account for differences in head size. 
 
Association between DM2 Diagnosis and Outcome Measures 
 After controlling for the effects of BMI, MMSE, GDS, age, sex, and education, 
DM2 was still associated with lower RAVLT learning  (p=0.0115) and recognition scores 
(p=0.0422). For the FNAME measures, DM2 remained a significant predictor of total 
FNAME task performance (p=0.0006), face-name learning, recall and recognition 
(p=0.0015), face-name learning (p=0.0005), face-occupation recall (p=0.0124), face-
name recall (p=0.0010), face-name recognition (p=0.0023), and face-occupation 
recognition (p=0.0345) after the adjustment. 
Interestingly, when adjusting for the same variables, higher HbA1c levels were 
significantly associated with most but not all tasks. Higher HbA1c was still associated 
with lower recognition (p=0.0086), FNAME task performance (p=0.0177), face-name 
learning, recall and recognition (p=0.0089), face-name learning (p=0.0080), face-name 
recall (p=0.0080), and face-name recogniton (p=0.0261). No associations were found 
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between HbA1c levels and RAVLT learning (p=0.1402) and face-occupation recogniton 
(p=0.1691).  
Association between episodic memory performance and brain structure 
 
In the DM2 group, there were no associations found between immediate recall 
and grey matter volume in the regions-of-interest. However, there were significant 
associations between higher scores on long-term memory retrieval measures (delayed 
recall and delayed recognition) and lower right amygdala volume (RAVLT delayed 
recall: p=0.044; RAVLT delayed recognition: p=0.044). Therefore, in individuals with 
DM2, memory consolidation and retrieval may be mediated by the amygdala. Lower 
right amygdala was also associated with lower face-occupation recognition in the DM2 
group (p=0.0452). This suggests that face-occupation associative memory may be 
similarly mediated by the amygdala. In the DM2 group, lower left angular gyrus was also 
significantly associated with higher total FNAME sccores (p=0.0131), face-name recall 
(p=0.008), and face-name recognition (p=0.0310) scores. Thus, this higher-level episodic 
memory process of forming and retrieving face-name associations may require input 
from the DMN network specifically the angular gyrus.  
In the control group, lower RAVLT recall scores was associated with lower right 
posterior cingulate volume (p=0.0428), which is another area of the DMN network that 
plays a role in episodic memory retrieval. Lower RAVLT recognition scores were 
associated with lower left entorhinal volume (p=0.0349). These findings suggest that 
impairments verbal memory consolidation and retrieval may be due to affected regions 
other than the hippocampus. Interestingly, only in the control group were there 
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associations with the cognitive measures and hippocampal volume. Specifically, 
decreasing face-occupation associative memory scores were associated with decreases in 
hippocampal volume. This includes total face-occupation scores (p=0.0481), face-
occupation recall (p=0.0411) and face-occupation recognition (p=0.0456).  
When looking at the association between age and structural measures, increasing 
age was significantly associated with reductions in left hippocampal volume in the OHC 
group (p=0.004). However, even after controlling for age, decreased face-occupation 
associative memory performance was still significantly associated with reductions in left 
hippocampal volume. 
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DISCUSSION 
 
Most DM2 research has focused on DM2-related complications of the peripheral 
and autonomic nervous system. However, DM2 can also affect the CNS by inducing 
lasting cognitive abnormalities and accelerating the rate of cognitive aging. The impact of 
DM2 nonetheless contributes to cognitive deficits and exacerbates functional 
impairments and depressive symptoms that are commonly reported in DM2. CNS-related 
complications that are undetected and untreated may result in show poor adherence to 
treatment and poor diabetes control.90 Moreover, the increasing prevalence and financial 
burden of DM2 and dementia management will pose a challenge to our already strained 
health care system. It is therefore critical to identify if DM2 is in fact a risk factor for AD. 
If so, then the specific brain changes and cognitive profile must be well understood so 
that these cases can be detected and treated prior to permanent brain damage and 
irreversible cognitive dysfunction.  
The findings of this analysis contribute to the knowledge of episodic memory 
performance in DM2 and structural changes in associated brain regions. Two types of 
episodic memory were chosen, one in verbal learning and memory, and the other in 
paired-associative memory. Impairments in paired-associative memory were more 
significantly impaired in the DM2 group than impairments in verbal learning and 
memory. This could be because semantically unrelated words, such as the list of 10 
words of the RAVLT, allows one to categorize each world and more easily retrieve them 
from his or her memory. Thus, the RAVLT captures a more simple episodic memory 
process. Additionally, similar previous studies, this analysis failed to report significant 
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reductions in the formation and retrieval face-occupation pairs,61 aside from a delayed 
recall after 30 minutes. Perhaps DM2 did not predict impairments retrieving face-
occupation associations because one can rely on previously stored semantic knowledge. 
Yet, long-term retrieval of face-occupation associations is impaired in DM2, which is a 
more complicated process of long-term memory. Ultimately, the formation of face-name 
associations is a more complex process compared with the RAVLT measures and the 
face-occupation measures because there are no contextual properties with which to form 
the associative link.61 Therefore, forming this association requires a higher level of 
cognitive demand. The results suggest that the FNAME task is a sensitive marker for the 
earliest stages of cognitive decline or accelerated brain aging. Moreover, DM2 may 
predict accelerating aging and a decline in forming face-name associations. Thus, the 
FNAME may be a reliable tool for the early detection and prevention of these changes.  
The impairments in episodic memory remained significant even after controlling 
for age, BMI, global cognitive status (MMSE), depression, sex and education. An 
identical model was created using HbA1c levels, rather than diagnosis, as a predictor of 
episodic memory performance. This model supports that HbA1c is also a reliable 
predictor of episodic memory performance. Therefore, the results from the cognitive 
measures suggest that both DM2 and HbA1c are predictors of episodic memory 
impairments and are independent of potential confounders.  
For the structural outcome measures, the results of this analysis are inconsistent 
with reports of medial temporal lobe grey matter volume reductions in individuals with 
DM2 compared with controls. This analysis did not find significant decreases, or 
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reductions at all, in commonly reported areas of the episodic memory network: the 
amygdala, the precuneus, the anterior cingulate cortex, and the angular gyrus. A 
marginally significant reduction was found in the right posterior cingulate cortex. This 
analysis found reductions in global gray matter volume, including both cortical and 
subcortical structures. The results were only significant on a p<0.10 level. However, it is 
important to note that the lack of statistical significance could be due to the small sample 
size rather than clinical importance. The results of the structural analysis are consistent 
with previous studies that did not find hippocampal reductions in DM2, but had instead 
found global reductions in grey matter volume. However, after controlling for age, the 
association of this analysis was not as strong. Therefore, the reduction could have been 
due to the fact that the DM2 group was older on average, rather than the effect of 
diabetes.   
In looking at within-group associations between cognitive and structural 
measures, interesting associations were found and discussed in the results. However, 
these differences are not of clinical significance since the DM2 group did not show any 
reductions in grey matter volume alone in the regions of interest. Additionally, not all 
regions of the medial temporal lobe and default mode network were associated with 
episodic memory performance, suggesting that the entire network and its dynamic 
communication may not be affected in DM2 as it is in preclinical AD or AD. 
 Several limitations of this analysis must be discussed. First, the small sample size 
may hinder the power of the analysis. The sample size was enough to detect significant 
differences in memory, particularly in paired-associative memory, even after controlling 
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for variables that may confound the relationship, such as BMI, self-reported depression, 
and age. However, the small sample size may have hidden true difference between the 
DM2 and control group in structural volume as well as in baseline characteristics such as 
general cognition or intelligence. Additionally, recent literature reports that effect sizes to 
detect impairments in cognitive functioning range from 0.4 to 1.0.91 If a sample size 
calculation were to be performed before the study, to find a moderate effect size of 0.4 
with a standard deviation of 0.5, 80% power, and an alpha of 0.05, each study arm would 
need to have 26 subjects. Therefore the results found only on the FNAME task would be 
underpowered. Another statistical limitation is that although significant differences were 
found, this analysis did not correct for multiple comparisons, which also increases the 
likelihood of a type I error.  
Another limitation is the generalizability of the analysis, as patients from the 
Joslin Diabetes Center are those who are receiving care for DM2 from a specialist as 
opposed to a primary care physician. Therefore, the individuals in this analysis may have 
poorly controlled DM2 and resultant irreversible cognitive damages, and the results 
would not apply to those with early stages or well-controlled DM2 who are only being 
seen by a PCP. Additionally, in our population, there are several individuals with 
undetected DM2, and many who cannot access or afford treatment of DM1. Therefore, 
the consequences of diabetes on these poorly controlled individuals may be different, as 
they are not receiving treatment through oral agents or insulin. A similar limitation 
applies to the control subjects. There were individuals with HbA1c levels in the pre-
diabetes range. Since HbA1c is the average glycosylated hemoglobin in the past 3 
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months, those with elevated HbA1c levels may have had HbA1c levels in the diabetes 
range (>6.4%) in the past. As a result, they may have already developed DM2-related 
brain changes. Therefore, this analysis included individuals with pre-diabetes who were 
not true controls to the DM2 group, and this may have hindered true differences between 
individuals with and without DM2. 
Another limitation is the lack of access to all study charts to control for the 
potentially confounding effect of hypertension, high cholesterol, and genetic risk on the 
outcome measures. This lack of information may affect the results of the study. For 
example, cases of dementia may be mediated by vascular risk factors besides DM2. 
These risk factors are comorbidities of DM2 and include hypertension, high cholesterol 
and obesity. In 2009, a systematic review showed that these four risk factors were 
associated with a decrease in cognitive functioning, but the significance was highest for 
diabetes and obesity. 92 Another study showed, however, that learning memory were 
significantly impaired, but when the analysis was adjusted for the presence of 
hypertension, the difference was not significant.93 In this analysis, both groups included 
individuals who were receiving lipid-lowering and blood pressure medications. This 
analysis controlled for BMI, but the true differences between groups may be masked if 
control subjects had hypertension and cholesterol. Moreover, the structural and cognitive 
changes detected may be exacerbated by the presence hypertension and high cholesterol 
in the DM2 group. Therefore, future studies should examine the independent effect as 
well as the interactions of these risk factors with DM2 on as predictors of structural and 
cognitive measures. Lastly, genetic predisposition could also have a modulating effect on 
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the relationship between DM2 and the outcome measures, specifically the presence of the 
E4 allele of the Apolipoprotein E (APOE) is a gene on chromosome 9. Individuals who 
are heterozygous for the E4 allele have a 4-fold risk of developing AD, while 
homozygous individuals are at a 9-fold increased risk.9 This analysis did not adjust for 
the genetic risk of developing AD, which could result in a false positive association 
between DM2 and the outcome measures.    
 It is important to note the clinical significance of the cognitive measures reported 
in this analysis. The study protocol of this analysis used a 10-word list for the RAVLT, 
which is a modified form of the original 15-word version. There are no norms published 
for the modified version. Although the DM2 group performed significantly worse on 
measures of learning and recognition, indicating impaired verbal learning and long-term 
memory, the decrease in performance of the DM2 group may not be clinically 
meaningful. Similarly, the FNAME task has published norms for different age groups, 
but not for the version of the task that the study protocol used.  
 Future studies are needed to further investigate the link between DM2 and AD, as 
well as to specify the etiology of brain changes due to DM2 directly. A future study could 
enroll individuals at the pre-diabetes stage and assess episodic memory performance and 
structural MRI changes longitudinally. This study design would give insight into changes 
that may occur as early as the pre-diabetes phase. If there are changes, individuals should 
be followed and treated for these changes prior to DM2 diagnosis. Secondly, this analysis 
consisted of several regions of the episodic memory network. There is little evidence of 
grey matter reductions in these regions. A future study could take a large database of 
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DM2 subjects (n>100) for whom there are structural MRIs. A whole brain morphometry 
analysis should be performed to isolate specific that have gray matter volume loss in 
DM2 compared with controls. Then, a ROI-based morphometry analysis can therefore be 
performed that associates episodic memory performance to grey matter volume in the 
more specific ROIs.  
One important finding of this analysis is the marginally significant reductions in 
posterior cingulate cortex volume in lieu of the small sample size. A follow-up study 
should be performed to focus on posterior cingulate cortex volume in DM2. Posterior 
cingulate cortex reductions are reported in mild, moderate and severe cases of AD. 
Furthermore, the functional connectivity of the posterior cingulate cortex to other regions 
of the DMN is reduced, and this reduction in connectivity is exacerbated with increasing 
AD severity.33 A future cross-sectional study should take a larger sample of individuals 
with and without DM2 and examine both gray matter volume of the posterior cingulate 
cortex and functional connectivity with the hippocampus and other DMN regions.  
This analysis concludes that there are significant impairments in episodic memory 
individuals with DM2. There is not enough evidence to conclude that grey matter volume 
of brain regions in the episodic memory network is associated with these impairments in 
episodic memory formation and retrieval. The results of the analysis nonetheless 
contribute to the need of validated neuropsychological measures, such as the FNAME 
task, that measure higher-level cognitive functions in conjunction imaging-based 
biomarkers of cognitive decline in population-based studies of DM2. Together, these 
tools can help identify and predict risk factors of cognitive decline prior to AD onset. 
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